KLOW (80 mg Vial) Dosage Protocol

KLOW (80 mg Vial) Dosage Protocol

#dosing-schedule .dr-container > header { margin-bottom: 0 !important; padding-bottom: 0 !important; }
#dosing-schedule .dr-container > header * { margin-bottom: 0 !important; }
#dosing-schedule .dr-container > header::before, #dosing-schedule .dr-container > header::after { content: none !important; display: none !important; }
#dosing-schedule .dr-container > section:first-of-type { margin-top: 0 !important; display: flow-root; }
#dosing-schedule .dr-container > section:first-of-type h2:first-child { margin-top: 0 !important; }
#dosing-schedule .dr-container .wp-block-spacer, #dosing-schedule .dr-container hr { display: none !important; height: 0 !important; margin: 0 !important; border: 0 !important; }

Quickstart Highlights

KLOW is an 80 mg lyophilised blend containing GHK-Cu (50 mg) + TB-500 (10 mg) + BPC-157 (10 mg) + KPV (10 mg). It builds on the GLOW formula by adding KPV — a potent anti-inflammatory tripeptide — making it the most comprehensive blend for recovery contexts involving gut or systemic immune involvement alongside tissue injury.[1][2]

  • Reconstitute: Add 4.0 mL bacteriostatic water → 20.0 mg/mL concentration.
  • Standard dose: 2,000 mcg (10 units / 0.10 mL) once daily subcutaneous.
  • Easy measuring: At 20.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 200 mcg total blend.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks. Note: KLOW solution appears blue due to the GHK-Cu copper chelation — this is normal.
KLOW 80mg Vial

Dosing & Reconstitution Guide

Educational daily protocol for the KLOW four-peptide blend

Standard Daily Protocol (4.0 mL = 20.0 mg/mL)

Week(s) Total Dose Units (U-100) Volume GHK-Cu TB-500 BPC-157 KPV
Weeks 1–2 (starting) 1,000 mcg 5 units 0.05 mL ~625 mcg ~125 mcg ~125 mcg ~125 mcg
Weeks 3–4 (standard) 2,000 mcg 10 units 0.10 mL ~1,250 mcg ~250 mcg ~250 mcg ~250 mcg

Frequency: Inject once daily subcutaneously. Begin at the half-dose for the first 1–2 weeks to assess tolerability, then advance to the standard 2,000 mcg dose. At 20.0 mg/mL, the 80 mg vial provides 40 days at the 2,000 mcg/day standard dose or a full 28-day cycle with flexibility for dose titration.

Cycle structure: 4 weeks on, 2–4 weeks off. The rest period allows assessment of healing progress before deciding on a second cycle.

Reconstitution Steps

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 4.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall to minimise foaming; do not inject directly onto the powder cake.
  4. Gently swirl or roll until fully dissolved — do not shake. Note: KLOW solution will appear blue due to the copper chelation of GHK-Cu; this is normal and expected.
  5. Label with reconstitution date and all four component names; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 4-week cycle at 2,000 mcg once daily (28 injections).

  • KLOW Vials (80 mg each): One 80 mg vial provides a full 40-day supply at 2,000 mcg/day → 1 vial per cycle.
  • Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 28 injections → 28 syringes per 4-week cycle.
  • Bacteriostatic Water (10 mL bottles): 4.0 mL per vial → 1 × 10 mL bottle per 2 vials.
  • Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.
KLOW 80mg
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Composition: GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg (4:1:1:1 ratio) in an 80 mg lyophilised vial.
  • Goal: Comprehensive tissue repair with additional gut-lining and systemic anti-inflammatory support via KPV.[1][2]
  • Schedule: Once-daily SC injection for a 4-week cycle; 2–4 weeks off.
  • Reconstitution: 4.0 mL BAC water per 80 mg vial → 20.0 mg/mL.
  • Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

Dosing Protocol

  • Weeks 1–2 (starting): 1,000 mcg (5 units / 0.05 mL) once daily — half-dose tolerability phase.[2]
  • Weeks 3–4 (standard): 2,000 mcg (10 units / 0.10 mL) once daily.
  • Each standard injection delivers: ~1,250 mcg GHK-Cu + ~250 mcg TB-500 + ~250 mcg BPC-157 + ~250 mcg KPV.
  • Injection site: Abdomen, thigh, or upper arm (rotate daily). For injuries with a strong local component, proximity to injury site enhances BPC-157’s local effects.

Storage Instructions

  • Lyophilised: Store at −20 °C (−4 °F) or below; protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Blue colour: GHK-Cu copper chelation gives the solution a characteristic blue colour — inspect for clarity but do not expect the colourless appearance of other peptides.

Important Notes

  • KLOW solution is normally blue — this is expected and indicates intact GHK-Cu copper chelation. Do not discard on this basis alone.
  • KLOW is particularly suited to recovery contexts involving gut inflammation (NSAID use, IBD flares, stress-related gut dysfunction) where KPV’s mucosal protection adds meaningful benefit over the GLOW blend.
  • WADA-prohibited — TB-500 and BPC-157 are Category S2 non-approved peptides. Athletes under anti-doping rules must not use KLOW.
  • Rotate injection sites daily; document dose, site, and any local reactions.

How This Works

KLOW combines four peptides into a single coordinated repair and anti-inflammatory protocol:

  • GHK-Cu (50 mg — primary component): Copper tripeptide that modulates 4,000+ repair genes, stimulates collagen synthesis (types I, III, IV), balances MMPs/TIMPs, and delivers bioavailable copper to cuproenzymes (lysyl oxidase, SOD1).[2]
  • TB-500 (10 mg): Binds G-actin for systemic cell migration, angiogenesis, anti-inflammatory, and anti-fibrotic signalling body-wide.
  • BPC-157 (10 mg): Drives local repair via FAK-paxillin pathway, VEGF upregulation, and NO-pathway normalisation; provides additional gut mucosal protection.[3]
  • KPV (10 mg — KLOW’s distinguishing component): The C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Penetrates intestinal epithelial cells, inhibits NF-κB to reduce pro-inflammatory cytokines (IL-6, TNF-α) in gut mucosa, and acts on melanocortin receptors (MC1R, MC3R) for systemic immune modulation.[1]

The 4:1:1:1 ratio prioritises GHK-Cu’s broad genomic repair foundation while each supporting peptide contributes a distinct, non-overlapping mechanism.

Potential Benefits & Considerations

  • Gut and immune support: KPV significantly reduced colonic inflammation in experimental colitis, reducing TNF-α, IL-6, and NF-κB activity in intestinal tissue.[1]
  • Genomic repair: GHK-Cu modulates 4,000+ genes; 31/66 chronic disease genes shifted toward healthy phenotypes.[2]
  • Musculoskeletal repair: BPC-157 and TB-500 components provide local and systemic tissue repair — same evidence base as the Wolverine Stack.[3]
  • Blue solution: GHK-Cu’s copper chelation produces a characteristic blue colour — document this in protocol notes to avoid confusion.
  • WADA status: TB-500 and BPC-157 components are prohibited; GHK-Cu and KPV have no explicit WADA prohibition as of 2025 but KLOW as a blend is non-approved.

Lifestyle Factors

  • Maintain adequate dietary protein (1.2–1.6 g/kg) and vitamin C (collagen cofactor) for GHK-Cu’s collagen synthesis effects.
  • For gut inflammation contexts, a low-FODMAP or anti-inflammatory diet supports KPV’s mucosal repair effects.
  • Protect skin from UV exposure during GHK-Cu cycles — new matrix formation increases photosensitivity.
  • Avoid NSAIDs during KLOW cycles — they counteract BPC-157’s NO-pathway and VEGF repair signalling.

Injection Technique

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold)[CDC].
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

References


  • Dalmasso G et al. — PMC (2015) — KPV in Inflammatory Bowel Disease
    — KPV (Lys-Pro-Val) significantly reduced colonic inflammation in experimental colitis via NF-κB inhibition and melanocortin receptor activation
    View Source

  • Pickart L & Margolina A — MDPI International Journal of Molecular Sciences (2018)
    — GHK-Cu: regenerative and protective actions; modulation of 4,000+ repair genes; 31/66 chronic disease genes shifted toward healthy phenotypes
    View Source

  • Gwyer D et al. — PMC (2025) — BPC-157 Orthopaedic Review
    — Comprehensive preclinical evidence for BPC-157 in musculoskeletal repair; FAK-paxillin pathway and VEGF mechanisms
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source